Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Redx Pharma making solid progress on cancer treatments, Cantor says

Cantor Fitzgerald has repeated a 'buy' rating on Redx Pharma after the company reported progress on the development of cancer treatments
Redx
Cantor reiterates a 'buy' rating on Redx Pharma

Redx Pharma Plc (LON:REDX) has enjoyed a productive year with two potentially best-in-class cancer treatments, Cantor Fitzgerald said today.

In its full year results yesterday, the drug maker reported progress of its development of its treatments.

The group's pipeline includes the Porcupine RXC004 treatment for pancreatic, biliary and gastric cancer, which will enter its first in-human studies following a clinical trial application (CTA) submission in the second quarter.

Redx is also developing leukaemia treatment BTK RXC005 and plans to make an investigational new drug application and CTA towards the end of 2017.

Cantor Fitzgerald reiterated a ‘buy’ rating on the stock and a target price of 105.0p, saying 2016 has been an “important year for Redx with solid process from the discovery engine” with molecules in focus areas of oncology and immunology.

“The first of these (a porcupine inhibitor) has overcome limitations which have blighted this approach (wnt pathway) elsewhere and is scheduled to enter the clince in mid-2017 targeting difficult to treat cancers.

“Elsewhere the BTK programme is progressing towards the clinic and remains a highly attractive asset in a very lucrative area (haematological cancers).”

Cantor said its recent £12mln fundraising has provided Redx with sufficient funds to allow it to deliver its lead RXC004 into clinic trials as well as progress the development of RXC005, which is expected to enter the clinic in early 2018.

The broker also welcomed Redx’s restructuring, which includes plans to cut jobs by 60%, to achieve estimated cost savings of about £4.2mln. 

“Redx has now refocused, is aiming to material reduce headcount (circa 60%), principally to capitalise on its clinical assets, while retaining its impressive research engine and funding its anti-infectives research through external collaborations.”

View full REDX profile View Profile

Redx Pharma Plc Timeline

CN Research
April 06 2017

Related Articles

shutterstock_255595165.jpg
July 26 2016
Chief executive Cameron Reynolds told Proactive: "It's one thing to be a science project. It's another to have products and we are right on the cusp of that.”
eye-766166_1280_583251a48f148.jpg
November 21 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.
brokerreport.jpg
January 25 2017
Analyst Vadim Alexandre, of the company’s broker Northland Capital, said Wednesday’s update provided “better visibility” on the trial timetable.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use